MX2009010409A - Agonistas kappa-opiaceos para el tratamiento del sindrome de colon irritable alternado con diarrea predominante. - Google Patents

Agonistas kappa-opiaceos para el tratamiento del sindrome de colon irritable alternado con diarrea predominante.

Info

Publication number
MX2009010409A
MX2009010409A MX2009010409A MX2009010409A MX2009010409A MX 2009010409 A MX2009010409 A MX 2009010409A MX 2009010409 A MX2009010409 A MX 2009010409A MX 2009010409 A MX2009010409 A MX 2009010409A MX 2009010409 A MX2009010409 A MX 2009010409A
Authority
MX
Mexico
Prior art keywords
diarrhea
ibs
predominant
bowel syndrome
irritable bowel
Prior art date
Application number
MX2009010409A
Other languages
English (en)
Spanish (es)
Inventor
Allen Mangel
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Publication of MX2009010409A publication Critical patent/MX2009010409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
MX2009010409A 2007-03-30 2008-03-07 Agonistas kappa-opiaceos para el tratamiento del sindrome de colon irritable alternado con diarrea predominante. MX2009010409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Publications (1)

Publication Number Publication Date
MX2009010409A true MX2009010409A (es) 2010-03-29

Family

ID=39795494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010409A MX2009010409A (es) 2007-03-30 2008-03-07 Agonistas kappa-opiaceos para el tratamiento del sindrome de colon irritable alternado con diarrea predominante.

Country Status (19)

Country Link
US (2) US7960429B2 (https=)
EP (3) EP2136801B1 (https=)
JP (2) JP5416085B2 (https=)
KR (2) KR101208326B1 (https=)
CN (2) CN102641265A (https=)
AU (1) AU2008232954A1 (https=)
BR (1) BRPI0809651A2 (https=)
CA (1) CA2682608A1 (https=)
CY (1) CY1113317T1 (https=)
DK (1) DK2136801T3 (https=)
ES (1) ES2393815T3 (https=)
HR (1) HRP20120798T1 (https=)
IL (1) IL201226A0 (https=)
MX (1) MX2009010409A (https=)
PL (1) PL2136801T3 (https=)
PT (1) PT2136801E (https=)
RU (1) RU2441655C2 (https=)
SI (1) SI2136801T1 (https=)
WO (1) WO2008121496A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682608A1 (en) 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
ES2906979T3 (es) 2016-12-21 2022-04-21 Tioga Pharmaceuticals Inc Formulaciones farmacéuticas sólidas de asimadolina
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
AU2021236662A1 (en) * 2020-03-18 2022-11-10 Cara Therapeutics, Inc. Oligosaccharide formulations of kappa opioid receptor agonists
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
JP7464744B2 (ja) * 2020-10-20 2024-04-09 セトラスホールディングス株式会社 診療支援装置、診療支援方法、診療支援プログラム及び診療支援システム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
EP0330467A1 (en) 1988-02-23 1989-08-30 Glaxo Group Limited Heterocyclic compounds
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5389686A (en) 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2021817C (en) 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
US5322848A (en) 1989-11-24 1994-06-21 Dr. Lo Zembeletti S.P.A. N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
AR019727A1 (es) 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
WO2003048113A1 (en) 2001-11-30 2003-06-12 Sepracor Inc. Tramadol analogs and uses thereof
WO2003097051A2 (en) * 2002-05-17 2003-11-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
US7164021B2 (en) 2002-09-18 2007-01-16 The Curators Of The University Of Missouri Opiate analogs selective for the δ-opioid receptor
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2682608A1 (en) * 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Also Published As

Publication number Publication date
US7960429B2 (en) 2011-06-14
JP2013173790A (ja) 2013-09-05
BRPI0809651A2 (pt) 2014-10-07
HK1139860A1 (en) 2010-09-30
AU2008232954A2 (en) 2011-12-01
KR20120058614A (ko) 2012-06-07
EP2636407A2 (en) 2013-09-11
CN101677997A (zh) 2010-03-24
RU2009140042A (ru) 2011-05-10
SI2136801T1 (sl) 2013-01-31
US8877800B2 (en) 2014-11-04
PL2136801T3 (pl) 2013-01-31
DK2136801T3 (da) 2012-12-17
EP2561870A1 (en) 2013-02-27
PT2136801E (pt) 2012-12-06
US20080242720A1 (en) 2008-10-02
CA2682608A1 (en) 2008-10-09
HRP20120798T1 (hr) 2012-11-30
CN102641265A (zh) 2012-08-22
EP2136801A1 (en) 2009-12-30
EP2636407A3 (en) 2013-11-06
WO2008121496A1 (en) 2008-10-09
US20110046174A1 (en) 2011-02-24
JP2010523492A (ja) 2010-07-15
RU2441655C2 (ru) 2012-02-10
JP5416085B2 (ja) 2014-02-12
KR20100016004A (ko) 2010-02-12
KR101263225B1 (ko) 2013-05-13
KR101208326B1 (ko) 2012-12-05
IL201226A0 (en) 2010-05-31
EP2136801A4 (en) 2010-05-26
CN101677997B (zh) 2012-05-09
ES2393815T3 (es) 2012-12-28
AU2008232954A1 (en) 2008-10-09
CY1113317T1 (el) 2016-04-13
EP2136801B1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
MX2009010409A (es) Agonistas kappa-opiaceos para el tratamiento del sindrome de colon irritable alternado con diarrea predominante.
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
MX2009006505A (es) Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para usarlas en el tratamiento de la presbiopia.
MX2010002317A (es) Derivados de indol sustituidos y metodos para su utilizacion.
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
PH12017500930A1 (en) Hsp90 inhibitor combinations
MX2010002316A (es) Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
JP2012017330A5 (https=)
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
AP2320A (en) Proline derivatives and their use as dipeptidyl peptidase IV inhibitors.
MX2010002319A (es) Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
MX2009001494A (es) 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
WO2008155533A3 (en) Phenothiazine compounds for treating mild cognitive impairment
PL2291329T3 (pl) System oczyszczania cieczy, zwłaszcza oczyszczania wody balastowej
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MY145817A (en) Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
MX2012000572A (es) Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.
GB201105050D0 (en) Pharmaceutical agent
EP4279130A3 (en) Use of fk506 for the treatment of pulmonary arterial hypertension
MX2012002895A (es) Metodos para tratar el sindrome de intestino irritado (ibs).
MY155340A (en) Use of cathepsin c
NO20082838L (no) 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter
WO2010047999A3 (en) Method for treating pulmonary arterial hypertension
TW200716159A (en) Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells

Legal Events

Date Code Title Description
FA Abandonment or withdrawal